UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) FORM 10-Q (State ...

| --- | --- | --- | --- | --- | --- | |---------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | INVESTOR | | | | | | | PRESENTATION NASDAQ: TNXP | | | | | | | Version P0322 September 27, 2021 (Doc 0903) | | | | | | © 2021 Tonix Pharmaceuticals Holding Corp. CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS 2 Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations o ...

1 Investor Presentation NASDAQ:TNXP P H A R M A C E U T I C A L S September 2021 Version P0318 9-7-2021 (Doc 0892) © 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) (State or o ...

TNX-102 SL for Fibromyalgia (FM) - TNX-102 SL achieved statistical significance in reducing daily pain (p=001) in the Phase 3 RELIEF study with 503 participants[26, 31] - In the RELIEF study, 468% of participants on TNX-102 SL achieved a 30% or greater reduction in pain, compared to 349% on placebo (p=006)[32] - The F304/RELIEF study showed that TNX-102 SL had nominally significant improvements in FIQ-R Symptom Domain (p=007), FIQ-R Function Domain (p=009), PROMIS Fatigue (p=018), Daily Sleep Quality (p<001), and PROMIS Sleep Disturbance (p<001)[38] - A second Phase 3 study, F306/RALLY, is ongoing with approximately 670 participants, with topline results expected in the first quarter of 2022[49, 51] COVID-19 Vaccine Candidates - TNX-1800, a COVID-19 vaccine candidate, demonstrated positive immune response in non-human primates, with undetectable SARS-CoV-2 by PCR in upper and lower airways after challenge[65] - TNX-1800 vaccination of non-human primates elicited anti-SARS-CoV-2 neutralizing antibodies (≥1:40 titer) in all eight animals at Day 14 after a single vaccination[87] - TNX-3500 (sangivamycin) is 65 times more potent than remdesivir in inhibiting SARS-CoV-2 in cell culture infectivity studies[129] - TNX-2300 is a second SARS-CoV-2 vaccine platform utilizing Bovine Parainfluenza (BPI) Virus[132] - TNX-2100 is a potential skin test to measure SARS-CoV-2 exposure and T cell immunity[138] Other Pipeline Programs - TNX-1300 (cocaine esterase) rapidly reversed the physiologic effects of cocaine, with cocaine plasma exposures dropping by 90% within two minutes in a Phase 2 study[146] - TNX-1900 (intranasal oxytocin) is being developed as a prophylactic treatment for chronic migraine, with a Phase 2 study expected to start in the third quarter of 2021[160, 172] - TNX-601 CR (tianeptine oxalate and naloxone HCl) is a controlled-release tablet for major depressive disorder (MDD), with a Phase 2 study expected to start in the fourth quarter of 2021[181, 184]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) (State or ...

1 Investor Presentation NASDAQ:TNXP April 2021 Version P0286 4-06-2021 (Doc 0815) © 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 Commission File Number 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 26-1434750 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 26 Main Street, Suite 101 Chatham, New Jersey 07928 (Address o ...

1 Investor Presentation NASDAQ:TNXP January 2021 Version P0267 1-5-2021 (Doc 0756) © 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "fore ...

1 Investor Presentation NASDAQ:TNXP November 2020 Version P0256 11-16-20 (Doc 0733) © 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "for ...